5[5]Erdogan c,Savci G,Effect of different threshold levels and injection rates on hepatic enhancement by using bolus tracking technique in helical CT[J].Tani Girisim Radyol,2003,9 (2):207.
6Helmberger T, Semelka RC. New contrast agents for imaging the liver. Magn Reson Imaging Clin N Am, 2001, 9:745-766.
7Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions :evaluation of the efficacy of gadobenate dimeglumine in MR imaging:a multicenter phase Ⅲ clinical study. Radiology. 2000, 215 : 727-736.
8Gallez B, Bacic G, Swartz HM. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP. Magn Reson Med,1996, 35: 14-19.
9Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol, 2000, 175:1111-1120.
10del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and erumoxides-enhanced MR imaging examinations. Radiology, 2002,225 : 766-772.
